SEC Form SC 13G filed by Black Diamond Therapeutics Inc.
$BDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $20.00 | Outperform | Raymond James |
| 7/14/2023 | Overweight | Piper Sandler | |
| 6/30/2023 | $2.00 → $10.00 | Hold → Buy | Stifel |
| 6/28/2023 | $11.00 | Neutral → Buy | H.C. Wainwright |
| 6/27/2023 | $10.00 | Neutral → Outperform | Wedbush |
| 3/29/2022 | Outperform → Neutral | Wedbush | |
| 3/22/2022 | Buy → Neutral | H.C. Wainwright | |
| 9/30/2021 | $10.00 | Hold | Stifel |
CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025 Webcasts will be available at the start of the presentations on the investor rel
The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancerBlack Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a
Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored "window of opportunity" trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 2025Cash, cash equivalents, and investments of $98.6 million as of December 31, 2024, expected to be sufficient to fund operations into Q4 2026 CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter an
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i
DEFA14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
DEF 14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
SCHEDULE 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
Raymond James initiated coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $20.00
Piper Sandler initiated coverage of Black Diamond Therapeutics with a rating of Overweight
Stifel upgraded Black Diamond Therapeutics from Hold to Buy and set a new price target of $10.00 from $2.00 previously
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir